Guggenheim Cuts Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $8.00

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Free Report) had its target price cut by Guggenheim from $12.00 to $8.00 in a research note issued to investors on Friday,Benzinga reports. They currently have a buy rating on the stock.

ZNTL has been the topic of several other reports. HC Wainwright reiterated a "buy" rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday. Wedbush upgraded shares of Zentalis Pharmaceuticals from an "underperform" rating to a "neutral" rating and set a $4.00 price objective on the stock in a report on Monday, August 12th. Finally, Oppenheimer restated an "outperform" rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $10.00.

Zentalis Pharmaceuticals Trading Down 12.2 %

Shares of NASDAQ ZNTL traded down $0.48 during midday trading on Friday, reaching $3.47. 1,832,087 shares of the stock were exchanged, compared to its average volume of 1,566,191. The company has a market capitalization of $247.27 million, a P/E ratio of -1.39 and a beta of 1.74. The stock has a 50 day moving average price of $3.42 and a 200-day moving average price of $5.42. Zentalis Pharmaceuticals has a 52-week low of $2.66 and a 52-week high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.36. On average, analysts forecast that Zentalis Pharmaceuticals will post -2.81 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. ProShare Advisors LLC raised its position in Zentalis Pharmaceuticals by 9.0% in the first quarter. ProShare Advisors LLC now owns 15,436 shares of the company's stock valued at $243,000 after purchasing an additional 1,274 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Zentalis Pharmaceuticals by 20.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company's stock worth $54,999,000 after acquiring an additional 585,644 shares during the period. Kennedy Capital Management LLC purchased a new position in Zentalis Pharmaceuticals in the 1st quarter worth approximately $189,000. Opaleye Management Inc. acquired a new stake in Zentalis Pharmaceuticals in the first quarter valued at approximately $3,152,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Zentalis Pharmaceuticals during the second quarter valued at approximately $58,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.